Polygenic hazard score to guide screening for aggressive prostate cancer: development and validation in large scale cohorts

Tyler M. Seibert(University of California San Diego), Chun Chieh Fan(University of California San Diego), Yunpeng Wang(Oslo University Hospital), Verena Zuber(Oslo University Hospital), Roshan Karunamuni(University of California San Diego), J. Kellogg Parsons(University of California San Diego), Rosalind A. Eeles(Royal Marsden NHS Foundation Trust), Douglas F. Easton(University of Cambridge), Zsofia Kote‐Jarai(Institute of Cancer Research), Ali Amin Al Olama(University of Cambridge), Sara Benlloch Garcia(University of Cambridge), Kenneth Muir(University of Manchester), Henrik Grönberg(Karolinska Institutet), Fredrik Wiklund(Karolinska Institutet), Markus Aly(Karolinska University Hospital), Johanna Schleutker(University of Turku), Csilla Sipeky(University of Turku), Teuvo L.J. Tammela(Tampere University Hospital), Børge G. Nordestgaard(University of Copenhagen), Sune F. Nielsen(University of Copenhagen), Maren Weischer(Gentofte Hospital), Rasmus Bisbjerg(Gentofte Hospital), Martin Andreas Røder(Copenhagen University Hospital), Peter Iversen(University of Copenhagen), Timothy J. Key(University of Oxford), Ruth C. Travis(University of Oxford), David E. Neal(John Radcliffe Hospital), Jenny Donovan(University of Bristol), Freddie C. Hamdy(John Radcliffe Hospital), Paul D.P. Pharoah(University of Cambridge), Nora Pashayan(University of Cambridge), Kay‐Tee Khaw(University of Cambridge), Christiane Maier(University Hospital Ulm), Walther Vogel(University Hospital Ulm), Manuel Luedeke(University Hospital Ulm), Kathleen Herkommer(TUM Klinikum), Adam S. Kibel(Brigham and Women's Hospital), Cezary Cybulski(International Hereditary Cancer Center), Dominika Wokołorczyk(International Hereditary Cancer Center), Wojciech Kluźniak(International Hereditary Cancer Center), Lisa Cannon‐Albright(University of Utah), Hermann Brenner(German Cancer Research Center), Katarina Ćuk(German Cancer Research Center), Kai-Uwe Saum(German Cancer Research Center), Jong Y. Park(Moffitt Cancer Center), Thomas A. Sellers(Moffitt Cancer Center), Chavdar Slavov(Alexandrovska Hospital), Radka Kaneva(Medical University of Sofia), Vanio Mitev(Medical University of Sofia), Jyotsna Batra(Queensland University of Technology), Judith A. Clements(Queensland University of Technology), Amanda B. Spurdle(Queensland University of Technology), Manuel R. Teixeira(Universidade do Porto), Paula Paulo(Instituto Português de Oncologia Francisco Gentil), Sofia Maia(Instituto Português de Oncologia Francisco Gentil), Hardev Pandha(University of Surrey), Agnieszka Michael(University of Surrey), Andrzej Kierzek(University of Surrey), David S. Karow(University of California San Diego), Ian G. Mills(Queen's University Belfast), Ole A. Andreassen(Oslo University Hospital), Anders M. Dale(University of California San Diego)
BMJ
January 10, 2018
Cited by 226Open Access
Full Text

Abstract

OBJECTIVES: To develop and validate a genetic tool to predict age of onset of aggressive prostate cancer (PCa) and to guide decisions of who to screen and at what age. DESIGN: Analysis of genotype, PCa status, and age to select single nucleotide polymorphisms (SNPs) associated with diagnosis. These polymorphisms were incorporated into a survival analysis to estimate their effects on age at diagnosis of aggressive PCa (that is, not eligible for surveillance according to National Comprehensive Cancer Network guidelines; any of Gleason score ≥7, stage T3-T4, PSA (prostate specific antigen) concentration ≥10 ng/L, nodal metastasis, distant metastasis). The resulting polygenic hazard score is an assessment of individual genetic risk. The final model was applied to an independent dataset containing genotype and PSA screening data. The hazard score was calculated for these men to test prediction of survival free from PCa. SETTING: Multiple institutions that were members of international PRACTICAL consortium. PARTICIPANTS: All consortium participants of European ancestry with known age, PCa status, and quality assured custom (iCOGS) array genotype data. The development dataset comprised 31 747 men; the validation dataset comprised 6411 men. MAIN OUTCOME MEASURES: Prediction with hazard score of age of onset of aggressive cancer in validation set. RESULTS: ). When men in the validation set with high scores (>98th centile) were compared with those with average scores (30th-70th centile), the hazard ratio for aggressive cancer was 2.9 (95% confidence interval 2.4 to 3.4). Inclusion of family history in a combined model did not improve prediction of onset of aggressive PCa (P=0.59), and polygenic hazard score performance remained high when family history was accounted for. Additionally, the positive predictive value of PSA screening for aggressive PCa was increased with increasing polygenic hazard score. CONCLUSIONS: Polygenic hazard scores can be used for personalised genetic risk estimates that can predict for age at onset of aggressive PCa.


Related Papers

No related papers found

Powered by citation graph analysis